COMPASS THERAPEUTICS INC

CMPXNASDAQ

🏆 #3724 by market capUS Equity

$1.09▼ $0.02 (−2.24%)

Market closed · at close

🔔

Track CMPX

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 2.2%

7d▼ 6.8%

14d▼ 40.6%

30d▼ 54.0%

ytd▼ 79.7%

1y▼ 68.8%

🏦Market Cap

$196M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $1.08 – $1.10
52-Week Range: $1.10 – $6.88
Volume: $4.03B
Avg Volume: $5.12B
Shares Outstanding: 180.1M
Next Earnings: Oct 31, 2026

Fundamentals Snapshot

Annual Revenue: $14M
Last Q Revenue: $3M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-0.31
Dividend Yield: —
Dilution (1yr): +35.3%

Why Investors Own CMPX

✓High-growth profile — revenue up +14.6% YoY with expanding US Equity exposure.
✓Healthy economics — 65% gross margin and 12% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

COMPASS THERAPEUTICS INC

CMPX

Financial Trends

Revenue

$0▼ −100.0% YoY

Operating Income

−$73M▲ +28.6% YoY

Free Cash Flow

−$49M▲ +9.5% YoY

Shares Outstanding

184.8M▲ +35.3% YoY

Net Cash

$21M▼ −$16M YoY

StockOtter · stockotter.space

About COMPASS THERAPEUTICS INC

Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.

🦦